Boston Scientific Corporation

Boston Scientific Corporation (BSX) – Gains from strategic acquisition

in , , on November 24, 2021

BSX structural heart programs are fast building momentum, banking on strong performance of the
WATCHMAN left atrial appendage closure device and ACURATE TAVR valve.

Highlights 

Valuation

– Enterprise Value
– CrispIdea Forecast
– DCF Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Acquisition
– Key Developments
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

CrispIdea Coverage

No of Pages : 39

Release Information

  • Price
    :

    $99.00

  • Released
    :

    November 24, 2021

  • Last Updated
    :

    December 2, 2021